Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: A nested-case-control study and a pooled meta-analysis

Breast Cancer Research and Treatment

Volumn 107, Issue 3, 2008, Pages 459-460

  Langsenlehner, Tanja ^a   Renner, Wilfried ^a   Yazdani Biuki, Babak ^a   Langsenlehner, Uwe ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2);

ARTICLE; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; DNA POLYMORPHISM; GENE FREQUENCY; GENOTYPE; HUMAN; META ANALYSIS; PREMENOPAUSE; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; META-ANALYSIS AS TOPIC; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, GENETIC;

EID: 38649141191     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9564-1     Document Type: Article

References (3)

1. Macis D, Maisonneuve P, Johansson H et al (2007) Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis. Breast Cancer Res Treat (in press). DOI 10.1007/s10549-006-9491-6
2. Langsenlehner U, Krippl P, Renner W et al (2003) The common 677C>T gene polymorphism of methylenetetrahydrofolate reductase gene is not associated with breast cancer risk. Breast Cancer Res Treat 81:169-172
3. Zintzaras E (2006) Methylenetetrahydrofolate reductase gene and susceptibility to breast cancer: a meta-analysis. Clin Genet 69:327-336